Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging

Rianna Vandergaast, Sarawut Khongwichit, Huailei Jiang, Timothy R DeGrado, Kah-Whye Peng, Duncan R. Smith, Stephen J Russell, Lukkana Suksanpaisan

Research output: Contribution to journalArticle

Abstract

Noninvasive bioluminescence imaging (BLI) of luciferase-expressing tumor cells has advanced pre-clinical evaluation of cancer therapies. Yet despite its successes, BLI is limited by poor spatial resolution and signal penetration, making it unusable for deep tissue or large animal imaging and preventing precise anatomical localization or signal quantification. To refine pre-clinical BLI methods and circumvent these limitations, we compared and ultimately combined BLI with tomographic, quantitative imaging of the sodium iodide symporter (NIS). To this end, we generated tumor cell lines expressing luciferase, NIS, or both reporters, and established tumor models in mice. BLI provided sensitive early detection of tumors and relatively easy monitoring of disease progression. However, spatial resolution was poor, and as the tumors grew, deep thoracic tumor signals were massked by overwhelming surface signals from superficial tumors. In contrast, NIS-expressing tumors were readily distinguished and precisely localized at all tissue depths by positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging. Furthermore, radiotracer uptake for each tumor could be quantitated noninvasively. Ultimately, combining BLI and NIS imaging represented a significant enhancement over traditional BLI, providing more information about tumor size and location. This combined imaging approach should facilitate comprehensive evaluation of tumor responses to given therapies.

Original languageEnglish (US)
JournalCancer Gene Therapy
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Reporter Genes
Neoplasms
Luciferases
Single-Photon Emission-Computed Tomography
Tumor Cell Line
Positron-Emission Tomography
Disease Progression
Thorax

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging. / Vandergaast, Rianna; Khongwichit, Sarawut; Jiang, Huailei; DeGrado, Timothy R; Peng, Kah-Whye; Smith, Duncan R.; Russell, Stephen J; Suksanpaisan, Lukkana.

In: Cancer Gene Therapy, 01.01.2019.

Research output: Contribution to journalArticle

@article{8d8de66b560b412cbf758d2f48c05427,
title = "Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging",
abstract = "Noninvasive bioluminescence imaging (BLI) of luciferase-expressing tumor cells has advanced pre-clinical evaluation of cancer therapies. Yet despite its successes, BLI is limited by poor spatial resolution and signal penetration, making it unusable for deep tissue or large animal imaging and preventing precise anatomical localization or signal quantification. To refine pre-clinical BLI methods and circumvent these limitations, we compared and ultimately combined BLI with tomographic, quantitative imaging of the sodium iodide symporter (NIS). To this end, we generated tumor cell lines expressing luciferase, NIS, or both reporters, and established tumor models in mice. BLI provided sensitive early detection of tumors and relatively easy monitoring of disease progression. However, spatial resolution was poor, and as the tumors grew, deep thoracic tumor signals were massked by overwhelming surface signals from superficial tumors. In contrast, NIS-expressing tumors were readily distinguished and precisely localized at all tissue depths by positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging. Furthermore, radiotracer uptake for each tumor could be quantitated noninvasively. Ultimately, combining BLI and NIS imaging represented a significant enhancement over traditional BLI, providing more information about tumor size and location. This combined imaging approach should facilitate comprehensive evaluation of tumor responses to given therapies.",
author = "Rianna Vandergaast and Sarawut Khongwichit and Huailei Jiang and DeGrado, {Timothy R} and Kah-Whye Peng and Smith, {Duncan R.} and Russell, {Stephen J} and Lukkana Suksanpaisan",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41417-019-0081-2",
language = "English (US)",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging

AU - Vandergaast, Rianna

AU - Khongwichit, Sarawut

AU - Jiang, Huailei

AU - DeGrado, Timothy R

AU - Peng, Kah-Whye

AU - Smith, Duncan R.

AU - Russell, Stephen J

AU - Suksanpaisan, Lukkana

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Noninvasive bioluminescence imaging (BLI) of luciferase-expressing tumor cells has advanced pre-clinical evaluation of cancer therapies. Yet despite its successes, BLI is limited by poor spatial resolution and signal penetration, making it unusable for deep tissue or large animal imaging and preventing precise anatomical localization or signal quantification. To refine pre-clinical BLI methods and circumvent these limitations, we compared and ultimately combined BLI with tomographic, quantitative imaging of the sodium iodide symporter (NIS). To this end, we generated tumor cell lines expressing luciferase, NIS, or both reporters, and established tumor models in mice. BLI provided sensitive early detection of tumors and relatively easy monitoring of disease progression. However, spatial resolution was poor, and as the tumors grew, deep thoracic tumor signals were massked by overwhelming surface signals from superficial tumors. In contrast, NIS-expressing tumors were readily distinguished and precisely localized at all tissue depths by positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging. Furthermore, radiotracer uptake for each tumor could be quantitated noninvasively. Ultimately, combining BLI and NIS imaging represented a significant enhancement over traditional BLI, providing more information about tumor size and location. This combined imaging approach should facilitate comprehensive evaluation of tumor responses to given therapies.

AB - Noninvasive bioluminescence imaging (BLI) of luciferase-expressing tumor cells has advanced pre-clinical evaluation of cancer therapies. Yet despite its successes, BLI is limited by poor spatial resolution and signal penetration, making it unusable for deep tissue or large animal imaging and preventing precise anatomical localization or signal quantification. To refine pre-clinical BLI methods and circumvent these limitations, we compared and ultimately combined BLI with tomographic, quantitative imaging of the sodium iodide symporter (NIS). To this end, we generated tumor cell lines expressing luciferase, NIS, or both reporters, and established tumor models in mice. BLI provided sensitive early detection of tumors and relatively easy monitoring of disease progression. However, spatial resolution was poor, and as the tumors grew, deep thoracic tumor signals were massked by overwhelming surface signals from superficial tumors. In contrast, NIS-expressing tumors were readily distinguished and precisely localized at all tissue depths by positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging. Furthermore, radiotracer uptake for each tumor could be quantitated noninvasively. Ultimately, combining BLI and NIS imaging represented a significant enhancement over traditional BLI, providing more information about tumor size and location. This combined imaging approach should facilitate comprehensive evaluation of tumor responses to given therapies.

UR - http://www.scopus.com/inward/record.url?scp=85060613882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060613882&partnerID=8YFLogxK

U2 - 10.1038/s41417-019-0081-2

DO - 10.1038/s41417-019-0081-2

M3 - Article

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

ER -